China Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry, Leaderna Therapeutics is advancing a new generation of siRNA medicines for chronic diseases, with programmes spanning hypertension, dyslipidaemia and obesity.…
Korea Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get innovative medicines to patients faster and at better prices. The same squeeze on generic margins, combined with new rewards for…
Europe Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional partnerships. She examines Europe’s evolving pharmaceutical landscape, from patent expiries and pricing pressure to growing attention on brain health, and…
India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
Korea We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum for the affiliate, driven by its fertility and oncology portfolios, as well as an improved access framework for innovative treatments…
Germany RNA interference (RNAi) therapeutics have the potential to redefine how certain diseases may be treated in the future, shifting the focus from managing symptoms to addressing their underlying biological cause. Having led the way in translating RNA interference from a scientific discovery into an established class of medicines, Alnylam Pharmaceuticals…
Europe The science only matters if we can bring those therapies to the people who need them As ophthalmology enters a new era shaped by aging populations, childhood myopia and medical advances, the role of healthcare companies is evolving. For Marianthi Psaha, President and Head of EMEA and International Pricing, Market…
Germany Dr Lasse Lehnert, General Manager of Chugai Pharma Germany and European Director for Customer Engagement and Digital Experience, discusses the unique Roche-Chugai strategic alliance, the challenges for continued delivery of pharmaceutical innovation in Germany, and how Chugai Pharma Europe is working to support patients, healthcare professionals and healthcare systems across…
Korea Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the company, including regional roles based in Tokyo before returning to head the Korean affiliate. He spoke to us about managing…
Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Europe The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet its ability to translate scientific excellence into timely and equitable patient access is becoming the defining challenge for the region’s…
See our Cookie Privacy Policy Here
